Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small-cell lung cancer

S. Frytak, E. G. Shaw, J. R. Jett, R. L. Richardson, R. L. Foote, E. T. Creagan, R. T. Eagan, J. Q. Su

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Sixty patients, 29 with limited disease and 31 with extensive disease, received an infusion cisplatin-based chemotherapy regimen and, where applicable, subsequent hyperfractionated thoracic radiation therapy (HTRT). Of the patients with limited disease, the response rate was 100% (76% complete response); median survival 26.5 months; 1- and 2-year survival 90 and 55%, respectively. Of those with extensive disease, 96% responded (36% complete response) with median survival 12.0 months and 1- and 2-year survival 48 and 29%, respectively. Thirty-five percent of extensive disease patients were downstaged to a 'limited' status, with a median survival of 20.3 months. Grade IV leukopenia and thrombocytopenia were seen in 25 and 7% of patients, respectively, with one patient dying of radiation pneumonitis. Within the constraints of the study, infusion cisplatin-based chemotherapy and HTRT appear to be a safe and effective program for the treatment of small-cell lung cancer.

Original languageEnglish (US)
Pages (from-to)193-198
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume19
Issue number2
DOIs
StatePublished - Apr 1996

Fingerprint

Small Cell Lung Carcinoma
Cisplatin
Radiotherapy
Thorax
Drug Therapy
Survival
Radiation Pneumonitis
Leukopenia
Thrombocytopenia

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small-cell lung cancer. / Frytak, S.; Shaw, E. G.; Jett, J. R.; Richardson, R. L.; Foote, R. L.; Creagan, E. T.; Eagan, R. T.; Su, J. Q.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 19, No. 2, 04.1996, p. 193-198.

Research output: Contribution to journalArticle

Frytak, S. ; Shaw, E. G. ; Jett, J. R. ; Richardson, R. L. ; Foote, R. L. ; Creagan, E. T. ; Eagan, R. T. ; Su, J. Q. / Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small-cell lung cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1996 ; Vol. 19, No. 2. pp. 193-198.
@article{30b8ecf7936740a58a1d2433998d4960,
title = "Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small-cell lung cancer",
abstract = "Sixty patients, 29 with limited disease and 31 with extensive disease, received an infusion cisplatin-based chemotherapy regimen and, where applicable, subsequent hyperfractionated thoracic radiation therapy (HTRT). Of the patients with limited disease, the response rate was 100{\%} (76{\%} complete response); median survival 26.5 months; 1- and 2-year survival 90 and 55{\%}, respectively. Of those with extensive disease, 96{\%} responded (36{\%} complete response) with median survival 12.0 months and 1- and 2-year survival 48 and 29{\%}, respectively. Thirty-five percent of extensive disease patients were downstaged to a 'limited' status, with a median survival of 20.3 months. Grade IV leukopenia and thrombocytopenia were seen in 25 and 7{\%} of patients, respectively, with one patient dying of radiation pneumonitis. Within the constraints of the study, infusion cisplatin-based chemotherapy and HTRT appear to be a safe and effective program for the treatment of small-cell lung cancer.",
author = "S. Frytak and Shaw, {E. G.} and Jett, {J. R.} and Richardson, {R. L.} and Foote, {R. L.} and Creagan, {E. T.} and Eagan, {R. T.} and Su, {J. Q.}",
year = "1996",
month = "4",
doi = "10.1097/00000421-199604000-00022",
language = "English (US)",
volume = "19",
pages = "193--198",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small-cell lung cancer

AU - Frytak, S.

AU - Shaw, E. G.

AU - Jett, J. R.

AU - Richardson, R. L.

AU - Foote, R. L.

AU - Creagan, E. T.

AU - Eagan, R. T.

AU - Su, J. Q.

PY - 1996/4

Y1 - 1996/4

N2 - Sixty patients, 29 with limited disease and 31 with extensive disease, received an infusion cisplatin-based chemotherapy regimen and, where applicable, subsequent hyperfractionated thoracic radiation therapy (HTRT). Of the patients with limited disease, the response rate was 100% (76% complete response); median survival 26.5 months; 1- and 2-year survival 90 and 55%, respectively. Of those with extensive disease, 96% responded (36% complete response) with median survival 12.0 months and 1- and 2-year survival 48 and 29%, respectively. Thirty-five percent of extensive disease patients were downstaged to a 'limited' status, with a median survival of 20.3 months. Grade IV leukopenia and thrombocytopenia were seen in 25 and 7% of patients, respectively, with one patient dying of radiation pneumonitis. Within the constraints of the study, infusion cisplatin-based chemotherapy and HTRT appear to be a safe and effective program for the treatment of small-cell lung cancer.

AB - Sixty patients, 29 with limited disease and 31 with extensive disease, received an infusion cisplatin-based chemotherapy regimen and, where applicable, subsequent hyperfractionated thoracic radiation therapy (HTRT). Of the patients with limited disease, the response rate was 100% (76% complete response); median survival 26.5 months; 1- and 2-year survival 90 and 55%, respectively. Of those with extensive disease, 96% responded (36% complete response) with median survival 12.0 months and 1- and 2-year survival 48 and 29%, respectively. Thirty-five percent of extensive disease patients were downstaged to a 'limited' status, with a median survival of 20.3 months. Grade IV leukopenia and thrombocytopenia were seen in 25 and 7% of patients, respectively, with one patient dying of radiation pneumonitis. Within the constraints of the study, infusion cisplatin-based chemotherapy and HTRT appear to be a safe and effective program for the treatment of small-cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0029986696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029986696&partnerID=8YFLogxK

U2 - 10.1097/00000421-199604000-00022

DO - 10.1097/00000421-199604000-00022

M3 - Article

C2 - 8610649

AN - SCOPUS:0029986696

VL - 19

SP - 193

EP - 198

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 2

ER -